These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 23543364)
1. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Xie X; Bartholomeusz C; Ahmed AA; Kazansky A; Diao L; Baggerly KA; Hortobagyi GN; Ueno NT Mol Cancer Ther; 2013 Jun; 12(6):1099-111. PubMed ID: 23543364 [TBL] [Abstract][Full Text] [Related]
2. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway. Li Y; Chen K; Li L; Li R; Zhang J; Ren W Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092 [TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664 [TBL] [Abstract][Full Text] [Related]
6. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Bartholomeusz C; Rosen D; Wei C; Kazansky A; Yamasaki F; Takahashi T; Itamochi H; Kondo S; Liu J; Ueno NT Cancer Res; 2008 Nov; 68(22):9302-10. PubMed ID: 19010903 [TBL] [Abstract][Full Text] [Related]
7. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel. Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells. Lee C Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442 [TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Chen H; Landen CN; Li Y; Alvarez RD; Tollefsbol TO Exp Cell Res; 2013 Mar; 319(5):697-706. PubMed ID: 23333498 [TBL] [Abstract][Full Text] [Related]
10. Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells. Huang KC; Yang J; Ng MC; Ng SK; Welch WR; Muto MG; Berkowitz RS; Ng SW Eur J Cancer; 2016 Nov; 67():152-163. PubMed ID: 27669502 [TBL] [Abstract][Full Text] [Related]
11. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin. Lee J; Bartholomeusz C; Krishnamurthy S; Liu P; Saso H; Lafortune TA; Hortobagyi GN; Ueno NT Oncogenesis; 2012 Jul; 1(7):e22. PubMed ID: 23552738 [TBL] [Abstract][Full Text] [Related]
12. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412 [TBL] [Abstract][Full Text] [Related]
13. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832 [No Abstract] [Full Text] [Related]
14. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355 [TBL] [Abstract][Full Text] [Related]
15. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways. Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374 [TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways]. Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551 [TBL] [Abstract][Full Text] [Related]
17. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456 [TBL] [Abstract][Full Text] [Related]
18. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. Zhan Y; Xiang F; Wu R; Xu J; Ni Z; Jiang J; Kang X J Ovarian Res; 2015 Jul; 8():48. PubMed ID: 26223974 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845 [TBL] [Abstract][Full Text] [Related]
20. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer. Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]